Ocugen Ties Executive Compensation to Regulatory Milestones

In a decisive move aligning leadership incentives with corporate goals, Ocugen, Inc. has established a substantial performance-based equity award for its Chief Executive Officer, Dr. Shankar Musunuri. The biotechnology firm’s board of directors approved a grant of nearly 9.4 million performance stock units, with the vast majority contingent upon achieving specific regulatory approvals by the end of 2028. This structure underscores the company’s strategic focus on advancing its gene therapy pipeline through key regulatory gates.

The board’s compensation committee authorized the grant on December 12, 2025, with an effective date of January 2, 2026. The award consists of 9,369,604 Performance Restricted Stock Units (PSUs).

This compensation plan features an unusually Read more...